S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in
NASDAQ:SBTX

Silverback Therapeutics Stock Forecast, Price & News

$45.64
+0.70 (+1.56 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$43.89
Now: $45.64
$47.15
50-Day Range
$25.00
MA: $38.42
$49.78
52-Week Range
$24.22
Now: $45.64
$54.41
Volume213,044 shs
Average Volume193,489 shs
Market Capitalization$1.51 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

151st out of 1,925 stocks

Analyst Opinion: 1.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBTX
CUSIPN/A
CIKN/A
Phone206-456-2900
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.51 billion
Next Earnings DateN/A
OptionableNot Optionable
$45.64
+0.70 (+1.56 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Silverback Therapeutics (NASDAQ:SBTX) Frequently Asked Questions

Is Silverback Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silverback Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Silverback Therapeutics stock.
View analyst ratings for Silverback Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Silverback Therapeutics?

Wall Street analysts have given Silverback Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Silverback Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Silverback Therapeutics' CEO?

1,448 employees have rated Silverback Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Silverback Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What price target have analysts set for SBTX?

4 brokers have issued twelve-month target prices for Silverback Therapeutics' shares. Their forecasts range from $40.00 to $58.00. On average, they anticipate Silverback Therapeutics' share price to reach $46.25 in the next twelve months. This suggests a possible upside of 1.3% from the stock's current price.
View analysts' price targets for Silverback Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Silverback Therapeutics' key competitors?

Who are Silverback Therapeutics' key executives?

Silverback Therapeutics' management team includes the following people:
  • Dr. Peter A. Thompson M.D., Co-Founder & Chairman of Directors (Age 62)
  • Dr. Valerie Odegard Ph.D., Pres & Chief Scientific Officer (Age 44, Pay $415.09k)
  • Dr. Naomi Hunder M.D., Chief Medical Officer (Age 52, Pay $426.54k)
  • Dr. Laura K. Shawver, CEO & Director (Age 63)
  • Mr. Jonathan Piazza, Chief Financial Officer (Age 46)
  • Mr. Jeffrey C. Pepe J.D., Ph.D., Sr. VP & Gen. Counsel
  • Katie Carrigan, VP of HR
  • Mr. Russ Hawkinson, Sr. VP of Fin.
  • Mr. Scott Moorefield Ph.D., Sr. VP of Bus. Devel.
  • Mr. Sateesh Natarajan, Sr. VP of CMC Devel.

When did Silverback Therapeutics IPO?

(SBTX) raised $126 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel served as the underwriters for the IPO and H.C. Wainwright was co-manager.

What is Silverback Therapeutics' stock symbol?

Silverback Therapeutics trades on the NASDAQ under the ticker symbol "SBTX."

When did Silverback Therapeutics' quiet period expire?

Silverback Therapeutics' quiet period expired on Wednesday, January 13th. Silverback Therapeutics had issued 11,500,000 shares in its public offering on December 4th. The total size of the offering was $241,500,000 based on an initial share price of $21.00. During Silverback Therapeutics' quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Silverback Therapeutics?

Shares of SBTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Silverback Therapeutics' stock price today?

One share of SBTX stock can currently be purchased for approximately $45.64.

How big of a company is Silverback Therapeutics?

Silverback Therapeutics has a market capitalization of $1.51 billion.

What is Silverback Therapeutics' official website?

The official website for Silverback Therapeutics is www.silverbacktx.com.

How can I contact Silverback Therapeutics?

The company can be reached via phone at 206-456-2900.

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.